The DOI matches its Crossref record, with a small difference in title or year; 12 of the 12 references it cites were found in a registry or an index.
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events
Open accessAbstract
BACKGROUND: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. OBJECTIVES: This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES. METHODS: Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death. RESULTS: With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk. CONCLUSIONS: In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationPrasugrel versus clopidogrel for acute coronary syndromes without revascularization
Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205512 · Cited by 874
Self-citationSchwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Self-citationShared Frailty Models for Recurrent Events and a Terminal Event
Liu, L., Wolfe, R. A., & Huang, X. (2004) · Biometrics · doi:10.1111/j.0006-341x.2004.00225.x · Cited by 340
Rondeau, V., Mathoulin-Pelissier, S., Jacqmin-Gadda, H., Brouste, V., & Soubeyran, P. (2006) · Biostatistics · doi:10.1093/biostatistics/kxl043 · Cited by 211
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome
Murphy, S. A., Cannon, C. P., Blazing, M. A., Giugliano, R. P., White, J. A., Lokhnygina, Y., Reist, C., Im, K., Bohula, E. A., Isaza, D., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.077 · Cited by 205
Murphy, S. A., Cannon, C. P., Wiviott, S. D., McCabe, C. H., & Braunwald, E. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.005 · Cited by 175
Television Viewing, Computer Use, Time Driving and All‐Cause Mortality: The SUN Cohort
Basterra‐Gortari, F. J., Bes‐Rastrollo, M., Gea, A., Núñez-Córdoba, J. M., Toledo, E., & Martínez‐González, M. Á. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.000864 · Cited by 98
Tikkanen, M., Szarek, M., Fayyad, R., Holme, I., Cater, N., Faergeman, O., Kastelein, J., Olsson, A., Larsen, M., Lindahl, C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.08.035 · Cited by 76
Self-citationLaRosa, J. C., DEEDWANIA, P. C., Shepherd, J., WENGER, N. K., Greten, H., DeMicco, D. A., & Breazna, A. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.025 · Cited by 66
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–174 of 174
Kirchhofer, D., Burdick, D. J., Skelton, N. J., Zhang, Y., & Ultsch, M. H. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190672 · Cited by 8
Duprez, D. A., Handelsman, Y., & Koren, M. J. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s261719 · Cited by 8
Baum, S. J., Wade, R. L., Xiang, P., Arellano, J., Olmos, C. C., Nunna, S., Chen, C., Carter, C. M., & Desai, N. R. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s216606 · Cited by 7
Reijnders, E., Bossuyt, P. M., Jukema, J. W., Ruhaak, L. R., Romijn, F. P. H. T. M., Szarek, M. J., Trompet, S., Bhatt, D. L., Bittner, V., Díaz, R., et al. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.322336 · Cited by 6
Self-citationWang, J., Han, P., Gao, M., Xiao, J.-Y., Li, X., Zhang, N., Ma, J., Cui, Z., Yao, T., Chen, Y., et al. (2021) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2021.05.002 · Cited by 6
Cequier, A. R., Arrarte, V., Campuzano, R., Castro, A., Cordero, A., Olmo, M. R. F., García–Moll, X., Gómez‐Doblas, J. J., de Sá, E. L., Núñez, J. E., et al. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2020.10.017 · Cited by 5
de Vries, T. I., Westerink, J., Bots, M. L., Asselbergs, F. W., Smulders, Y. M., & Visseren, F. L. J. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-038881 · Cited by 5
Rivera, F. B., Cha, S. W., Magalong, J. V., Bantayan, N. R. B., Cruz, L. L. A., Arias-Aguirre, E., Aguirre, Z., Varona, M. C., Co, E. M. F., Lumbang, G. N. O., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2363971 · Cited by 5
Context Analysis of Continued Citation of Retracted Manuscripts Published in Anesthesiology Journals
Frasco, P. E., Smith, B. B., Murray, A. W., Khurmi, N. S., Mueller, J. T., & Poterack, K. A. (2022) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006195 · Cited by 5
An Evidence-Based Guideline for Treating Dyslipidemia in Statin-Intolerant Patients
Lempp, D. (2021) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2021.06.005 · Cited by 5
Emerging therapies for refractory hypercholesterolemia: a narrative review
Pawlos, A., Khoury, É., & Gaudet, D. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2367860 · Cited by 4
Reduced adrenal stress response in patients on PCSK9 inhibitor therapy
Meier, S., Frick, M., Liu, M., Saravi, S. S. S., Montrasio, G., Preiss, H., Pasterk, L., Bonetti, N. R., Egloff, M., Schmid, H.-R., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.028 · Cited by 4
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13637 · Cited by 4
Evaluation of lipid services in the Republic of Ireland
Agar, R., Prendergast, M., & Maher, V. M. G. (2020) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-020-02187-6 · Cited by 4
Umate, R., Patil, M. S., Telrandhe, S., & Pathade, A. (2020) · Journal of Evolution of Medical and Dental Sciences · doi:10.14260/jemds/2020/386 · Cited by 4
PCSK9 inhibitors: role in reducing cardiovascular diseases
Malyarevskaya, O. V., Муратович, Н. А., Кручинова, С. В., & Kosmacheva, E. D. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-2-32-40 · Cited by 5
The cardiovascular benefit of Lp(a) reduction: not there yet
Pirillo, A., & Catapano, A. L. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa842 · Cited by 4
Ruhela, N., Singla, A., Trivedi, Y. V., Ahmed, M., Chikatimalla, R., Gupta, S., & Jain, R. (2025) · Coronary Artery Disease · doi:10.1097/mca.0000000000001574 · Cited by 5
Brie, D. M., Mornoş, C., Adam, O., Tîrziu, A., & Brie, A. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14186445 · Cited by 7
Bertolotti, M., Lancellotti, G., & Mussi, C. (2023) · Journal of Gerontology and Geriatrics · doi:10.36150/2499-6564-n637 · Cited by 3
Expert group from the Spanish Arteriosclerosis Society, Pedro‐Botet, J., López‐Miranda, J., Badimón, L., Civeira, F., Guijarro, C., Millán, J., Mostaza, J. M., Pintó, X., Valdivielso, P., et al. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00376-y · Cited by 3
van der Laarse, A., & Cobbaert, C. M. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2022475 · Cited by 3
Yan, Q., Wu, L., Song, J., Ye, L., Zhang, Q., Che, X., Zhang, X., & Wang, L. (2023) · Cardiology · doi:10.1159/000529365 · Cited by 3
Yao, Y., Qiu, Q., Wang, Z., Xu, S.-K., & Lv, Q. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00719-4 · Cited by 3
Optimal Non-invasive Strategies to Reduce Recurrent Atherosclerotic Cardiovascular Disease Risk
Jones‐O’Connor, M., & Natarajan, P. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0741-4 · Cited by 3
Residual Cardiovascular Risk Factors in Dyslipidemia
Nguyen, V. S., Tran, X. T., Vo, T. D., & Le, Q. T. C. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.100046 · Cited by 3
Szarek, M. J., Amarenco, P., Callahan, A. S., III, Goldstein, L. B., Sillesen, H. H., & Welch, K. M. A. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.06.042 · Cited by 3
Self-citationGene Silencing Therapeutics in Cardiology: A Review Article
Jay, P. Y., Maier, M. A., Saltonstall, L., Duarte, L., Antonino, I., & Vest, J. (2021) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200306 · Cited by 2
Noordam, R., Brochard, T. A., Drewes, Y. M., Gussekloo, J., Mooijaart, S. P., van Dijk, K. W., Trompet, S., Jukema, J. W., & van Heemst, D. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.011 · Cited by 2
Self-citationGhiasvand, T., Karimi, J., Khodadadi, I., Yazdi, A., Khazaei, S., Kichi, Z. A., & Hosseini, S. K. (2025) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2025.106969 · Cited by 2
2019 clinical trials in lipid lowering
Feldman, D. I., Pacor, J., Blumenthal, R. S., & Nasir, K. (2020) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000757 · Cited by 2
Kongmalai, T., Chuanchaiyakul, N., Srinoulprasert, Y., & Thongtang, N. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03804-5 · Cited by 2
Chionchio, A., Galmer, A. M., & Hirsh, B. J. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0791-7 · Cited by 2
Alirocumab after Acute Coronary Syndrome
Lan, N. S. R., Yeap, B. B., & Fegan, P. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1902955 · Cited by 2
Wang, Z., Chen, J., Zeng, Z., Zhang, Q., Du, G., Guo, X., & Wei, Y. (2021) · Research Square · doi:10.21203/rs.3.rs-885743/v1 · Cited by 2
Dey, H., Agarwal, V., Ali, M. N., Upadhyay, A., Shafieq, S., Dixit, B., Tomar, S., & Tarannum, M. (2024) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v14i4.6533 · Cited by 1
Wang, X., Liu, C., Yu, F., Zhang, Z., Wang, J., Shi, X., Xu, T., Deng, Q., Zhou, L., Sang, W., et al. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm25984 · Cited by 1
Liu, L., Yan, Q., Li, M., & Ai, J. (2025) · Current Problems in Surgery · doi:10.1016/j.cpsurg.2025.101964 · Cited by 1
Sakaguchi, E., Naruse, H., Ishihara, Y., Hattori, H., Yamada, A., Kawai, H., Muramatsu, T., Kitagawa, F., Takahashi, H., Ishii, J., et al. (2026) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-026-00609-y · Cited by 1
Nicolau, J. C., Murphy, S. A., Giugliano, R. P., Leiter, L. A., Ferrari, G. M. D., Park, J., Kuder, J., Liu, L., Wang, H., Shastri-Kumar, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.015 · Cited by 1
Abdelfattah, O., Sayed, A., Al-Refaei, A., Abdeldayem, J., Moustafa, K., Elias, N., & Saleh, Y. (2023) · Frontiers in clinical drug research. Diabetes and obesity · doi:10.2174/9789815123586123070008 · Cited by 1
Lusiki, Z., Blom, D. J., Soko, N. D., Malema, S., Jones, E. S. W., Rayner, B. L., Blackburn, J. M., Sinxadi, P., Dandara, M. T. L., & Dandara, C. (2023) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2023.0122 · Cited by 1
Tang, Y. (2024) · Springer eBooks · doi:10.1007/978-981-19-7712-1_1 · Cited by 1
Cardiology and Therapy: A Summary of 2019 and Key Areas of Emerging Research in 2020
Menown, I. B. A., Giugliano, R. P., & Zeymer, U. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00166-7 · Cited by 1
Lipidsenkende Therapie zur Sekundärprävention der peripheren arteriellen Verschlusskrankheit
Dopheide, J. F., & Drexel, H. (2020) · Gefässchirurgie · doi:10.1007/s00772-020-00629-0 · Cited by 1
Inhibiteurs PCSK9 en pratique clinique : données et interrogations
Vergès, B. L., Dubois, C., & Legris, P. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.010 · Cited by 1
Tuñón, J., Lázaro, A. M. P., López‐Castillo, M., & Aceñaa, Á. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30025-x · Cited by 1
The Cat Has 9 Lives, Until it Dies
Genest, J. J., & Nguyen, D.-V. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.025 · Cited by 1
PCSK9 Function and Cardiovascular Death
Schwartz, G. G., & Taylor, M. R. G. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.518 · Cited by 1
Self-citationPolymyositis, Dermatomyositis, and Statins: A Review
Turrin, M. (2018) · Clinical Management Issues · doi:10.7175/cmi.v12i1.1364
Pintó, X., & Sarasa, I. (2019) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2019.05.005
General Discussion and Future Perspectives
Cassarini, C. (2019) · CRC Press eBooks · doi:10.1201/9780429448300-7
Kanako, T., & Yokota, A. (2019) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.52.545
Escobar, C., & Barrios, V. (2020) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(20)30026-1
Emerging Therapies for Regulating Dyslipidaemias and Atherosclerosis
Ward, N. C., & Watts, G. F. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_33
Faculty Opinions recommendation of Effect of alirocumab on mortality after acute coronary syndromes.
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735819386.793563697
Consider old and new approaches when treating dyslipidaemia
Kim, E., & Lee, A. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00947-1
Gerő, L. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.11
Schwartz, G. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00036-4
Self-citationGenetic Risk Stratification Will Enhance Primary Prevention of Coronary Artery Disease
Roberts, R., & Acuna, E. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.1.4063
Inzucchi, S. E., Wanner, C., Fitchett, D., Zinman, B., Anker, S. D., Pocock, S., Mattheus, M., Hantel, S., & Lund, S. S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111715
Zahid, A., Batool, A., Khan, M. A., Ahmad, A., Ullah, A., & Wajid, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4684994/v1
Zahid, A., Batool, A., Khan, M. A., Ahmad, A., Ullah, A., & Wajid, A. (2024) · Research Square · doi:10.21203/rs.3.rs-4684994/v2
Detection and Treatment of Chronic Complications
Soe, K. K., & Gunasekaran, U. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch05
Chen, L., Li, M., Deng, Y., Chen, Z., Huang, R., Yang, X., & Huang, Z. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70072
Atherogenic index of plasma – a new frontier in predicting peripheral arterial disease risk?
Hohneck, A. L., & Weingaertner, O. (2025) · VASA · doi:10.1024/0301-1526/a001157
PCSK9 INHIBITORIŲ EFEKTYVUMAS GERINANT PACIENTŲ LIPIDŲ PROFILĮ PO MIOKARDO INFARKTO
Linkevičiūtė, G., & Černel, V. (2025) · Health Sciences · doi:10.35988/sm-hs.2025.215
Real-World and Subgroup Data Synthesis to Guide PCSK9 Inhibitor Use in Cardiovascular DiseasePreprint
Sun, L., Zhou, D., Hu, H., Ding, W., Zhong, Y., & Tian, L. (2025) · Research Square · doi:10.21203/rs.3.rs-7274417/v1
Peng, J., Liu, M.-M., Jin, J.-L., Yexuan, C., Guo, Y.-L., Wu, N.-Q., Zhu, C.-G., Dong, Q., Sun, J., Xu, R.-X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13059037
Dagenais, G. R., Rydén, L., Leiter, L. A., Lakshmanan, M. C., Dyal, L., Probstfield, J. L., Atisso, C. M., Shaw, J. E., Conget, I., Cushman, W. C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13290505
Genetic screening and response to drug therapy in familial hypercholesterolemia
Lu, Y., Chen, Q., Zhang, W., Dong, J., & Zha, L. (2026) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2026.1784302
Minutolo, R., Nicola, L. D., Cesaro, A., Cozzolino, M. G., Lullo, L. D., Iacoviello, M., Paoletti, E., Ravera, M., & Russo, V. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01434-y · Cited by 1
Peng, A. W., Minhas, A., Razavi, A. C., Kaul, S., & Blumenthal, R. S. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.08.045
Metadata
- Authors
- Szarek, M., White, H. D., Schwartz, G. G., Alings, M., Bhatt, D. L., Bittner, V. A., Chiang, C.-E., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Kimura, T., Kiss, R. G., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Roe, M. T., Tricoci, P., Xavier, D., Zeiher, A. M., & Steg, P. G.
- Affiliations
- State University of New York (US)
- University of Auckland (NZ)
- University of Colorado Anschutz (US)
- Amphia Ziekenhuis (NL)
- Brigham and Women's Hospital (US)
- University of Alabama at Birmingham (US)
- Taipei Veterans General Hospital (TW)
- Sanofi (United States) (US)
- St. Michael's Hospital (CA)
- Sanofi (France) (FR)
- Stanford University (US)
- Leiden University Medical Center (NL)
- Kyoto University (JP)
- Regeneron (United States) (US)
- Duke University (US)
- Goethe University Frankfurt (DE)
- Corresponding author
- Szarek, Michael
- ORCID
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 73
- Issue
- 4
- Pages
- 387-396
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2900103074
- Cited by
- 173
- References
- 12
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 18 · 2023: 15 · 2022: 18 · 2021: 17 · 2020: 45 · 2019: 42
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc-nd)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion, cc-by-nc-nd)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by-nc-nd)
- Lanzhou University Institutional Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Kyoto University Research Information Repository (Kyoto University) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, acute coronary syndrome, ODYSSEY OUTCOMES trial, PCSK9 inhibitors, all-cause mortality, shared frailty model, high-intensity statin therapy, myocardial infarction, stroke, coronary revascularization, unstable angina, heart failure
- MeSH terms
- Aged, Antibodies, Monoclonal, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
